You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
HER2 therapy: Molecular mechanisms of trastuzumab resistance
|
|---|---|
| Published in |
Breast Cancer Research, November 2006
|
| DOI | 10.1186/bcr1612 |
| Pubmed ID | |
| Authors |
Rita Nahta, Francisco J Esteva |
| Abstract |
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within one year of treatment initiation, and in the adjuvant setting 15% of patients still relapse despite trastuzumab-based therapy. In this review, we discuss potential mechanisms of antitumor activity by trastuzumab, and how these mechanisms become altered to promote therapeutic resistance. We also discuss novel therapies that may improve the efficacy of trastuzumab, and that offer hope that the survival of breast cancer patients with HER2-overexpressing tumors can be vastly improved. |
Mendeley readers
The data shown below were compiled from readership statistics for 313 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 1% |
| Italy | 1 | <1% |
| Austria | 1 | <1% |
| United Kingdom | 1 | <1% |
| Norway | 1 | <1% |
| Belgium | 1 | <1% |
| Mexico | 1 | <1% |
| Spain | 1 | <1% |
| Russia | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 301 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 66 | 21% |
| Student > Master | 48 | 15% |
| Student > Ph. D. Student | 44 | 14% |
| Student > Bachelor | 43 | 14% |
| Other | 15 | 5% |
| Other | 37 | 12% |
| Unknown | 60 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 92 | 29% |
| Medicine and Dentistry | 50 | 16% |
| Biochemistry, Genetics and Molecular Biology | 44 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 5% |
| Chemistry | 12 | 4% |
| Other | 31 | 10% |
| Unknown | 69 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#1,342,536
of 25,374,917 outputs
Outputs from Breast Cancer Research
#109
of 2,053 outputs
Outputs of similar age
#2,374
of 90,065 outputs
Outputs of similar age from Breast Cancer Research
#1
of 11 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 90,065 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.